Novartis had asked the justices to suspend a lower court#39;s ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company#39;s third highest-selling drug last year with $2.8 billion in sales.
Novartis had asked the justices to suspend a lower court#39;s ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company#39;s third highest-selling drug last year with $2.8 billion in sales.
English 
हिन्दी